Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer.

about

Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy.

P2860

Q55318335-75E1B52D-32C6-43CB-9AB1-E02EA3B394E5 Q55398181-2BC931EE-DCB0-4F43-9B07-1C258A45D266

P2860

Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer.

Item

http://www.wikidata.org/entity/Q49959323

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer.

@en

Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer.

@nl

type

Item

label

Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer.

@en

Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer.

@nl

prefLabel

Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer.

@en

Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer.

@nl

P1476

Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer.

@en

P2093

Martin Reck

http://www.w3.org/2001/XMLSchema#string

P2860

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer

PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

P304

93-105

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/IMT-2017-0121

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29145737

http://www.w3.org/2001/XMLSchema#string

Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer.

about

P2860

P2860

Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698